EMA Refused: Sumatriptan Galpharm (sumatriptan succinate) — Galpharm Healthcare Ltd.

View source ↗

Summary

The EMA refused approval for Sumatriptan Galpharm (sumatriptan succinate) by Galpharm Healthcare Ltd. for migraine disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• Sumatriptan Galpharm (sumatriptan succinate)

Snippet

Status: Refused. Therapeutic area: Migraine Disorders. MAH: Galpharm Healthcare Ltd.. Decision date: 09/02/2012